Compare SCHL & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCHL | FTRE |
|---|---|---|
| Founded | 1920 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.4M | 829.3M |
| IPO Year | 1995 | 2023 |
| Metric | SCHL | FTRE |
|---|---|---|
| Price | $39.24 | $14.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $40.00 | $14.06 |
| AVG Volume (30 Days) | 567.2K | ★ 1.5M |
| Earning Date | 03-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | $1,487,100,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $1.88 | N/A |
| Revenue Next Year | $4.05 | $3.09 |
| P/E Ratio | $20.65 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $16.78 | $3.97 |
| 52 Week High | $43.39 | $18.67 |
| Indicator | SCHL | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 66.30 |
| Support Level | $37.97 | $8.85 |
| Resistance Level | $39.65 | $18.26 |
| Average True Range (ATR) | 1.22 | 0.85 |
| MACD | -0.25 | 0.20 |
| Stochastic Oscillator | 44.56 | 70.27 |
Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.